← Eichor
Study identifier: NCT05377177 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI

Condition: Suicidal Ideation · Treatment-resistant Depression  ·  Sponsor: University of California, San Diego

PhaseNA
Planned participants76
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm. In this proposed study, the investigators will evaluate the anti-suicidal effects of bilateral aTBS over the DLPFC compared to accelerated intermittent theta burst stimulation (aiTBS) over the left DLPFC in participants with TRD and SI. Additionally, the investigators aim to identify neurophysiological targets through which bilateral aTBS induces remission of SI in TRD differentially from aiTBS.

This description comes directly from the study's public registry record.

Talk to the study team

Interventional Psychiatry  ·  (858) 657-6152  ·  iptrials@health.ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UCSD Interventional PsychiatrySan Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05377177